Deciphera Pharmaceuticals, Llc

This early-phase study tests a new oral drug, DCC-2812, in about 60 people with advanced kidney, bladder, or prostate cancer that has spread or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose, while also watching fo…

This study tests whether the drug vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants must have already tried at least two other treatments without success. They …

This study tests a new drug called DCC-3009, alone or with other cancer treatments, for people with advanced gastrointestinal stromal tumor (GIST) that has stopped responding to standard therapy. About 120 participants will receive the drug in 28-day cycles for up to 2 years. The…

This study tests a new drug called DCC-3116 combined with other cancer treatments for people with advanced GIST, a type of stomach or intestinal cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 94 adults whose cancer has worsened after stand…

This study looks at how a new drug called vimseltinib changes the way birth control pills work in healthy women. About 24 women will take both vimseltinib and a combined oral contraceptive, and researchers will measure drug levels in their blood. The goal is to see if vimseltinib…

This observational study follows 100 people with tenosynovial giant cell tumor (TGCT) who are taking vimseltinib as part of their normal care. Researchers will collect data on how long patients stay on the drug and how their quality of life changes. The study does not change or i…